Financial
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
HQ United Kingdom · Europe
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
Products not yet catalogued.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
No adverse media involving Brainomix found in HSH's search of the last 24 months. Feb 2026: the company raised a further £4.8m, taking its Series C to £18.8m, to fund US expansion.
No data breaches, cyber incidents, regulator action or published product vulnerabilities involving Brainomix found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
No recalls, safety notices or warning letters involving Brainomix products found in HSH's search of the last 24 months.
No contract terminations, disputes or troubled implementations involving Brainomix found in HSH's search of the last 24 months. A government-commissioned evaluation across 26 NHS sites reported higher thrombectomy rates at sites using Brainomix 360 Stroke (May 2024, outside the window).
No competitors linked yet.